Follow-up study of hyper-immune goat serum (Aimspro®) for amyotrophic lateral sclerosis (ALS)

Journal of Clinical Neuroscience

Volumn 16, Issue 11, 2009, Pages 1508-1509

  Mackenzie, R A ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AIMSPRO; HYPERIMMUNE GLOBULIN; HYPERIMMUNE GOAT SERUM; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; BREATHING MUSCLE; CLINICAL TRIAL; DISABILITY; DOSE RESPONSE; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EXPIRATORY RESERVE VOLUME; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; LETTER; LUNG FUNCTION TEST; MUSCLE STRENGTH; NORTH AMERICA; PARAPLEGIA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; GOATS; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOLOGIC FACTORS; INTERMITTENT POSITIVE-PRESSURE BREATHING; RESPIRATION; VITAL CAPACITY;

EID: 70449529395     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.03.019     Document Type: Letter

References (1)

1. Mackenzie R.A., Kiernan M., McKenzie D., et al. Hyperimmune goat serum for amyotrophic lateral sclerosis (ALS)-a new treatment option?. J Clin Neurosci 13 (2006) 1033-1036